medigraphic.com
ISSN 0188-9796 (Impreso)

2002, Número 2

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2002; 10 (2)


Avances en el tratamiento de las manifestaciones sensitivas de la neuropatía diabética

Gómez PFJ, Hernández JS, Rull, JA

Idioma: Español
Referencias bibliográficas: 59
Paginas: 77-83
Archivo PDF: 115.07 Kb.


RESUMEN

La neuropatía diabética es la complicación más frecuente de la diabetes. Su prevalencia está determinada por los métodos diagnósticos empleados y varía del 40 al 100%. Dado que es una condición que produce incapacidad funcional importante, dolor crónico y depresión, es necesario conocer sus mecanismos fisiopatológicos e identificar el tipo y grado de afección para establecer estrategias de prevención y tratamiento. Para este último se enfatizan las medidas iniciales como el control glucémico y ejercicio, y se describen los beneficios y efectos adversos de diferentes opciones farmacológicas disponibles.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gómez-Pérez FJ. Diabetes Sacarina. Cap. 3. En: Tratadode Medicina Interna. Jinich H, Woolrich J, Olivares L, ChávezI. (Eds.). Academia Nacional de Medicina. 1988: 178-218.

  2. Gómez-Pérez FJ. Complicaciones 1, En: “Fundamentos dela diabetes mellitus”. Gómez-Pérez FJ (Ed.) Grupo Mercadotecniade Innovación y Desarrollo SA de CV. México. 1997;15: 15-20.

  3. Pirart J. Diabetes mellitus and its degenerative complications:a prospective study of 4,400 patients observedbetween 1947 and 1973. Diabet Metab 1973; 3: 173-82.

  4. Paisey RB, Arredondo G, Villalobos A, Lozano-CastañedaO, Guevara L, Kelly S. Association of differing dietary,metabolic, and clinical risk factors with microvascularcomplications of diabetes: a prevalence study of 503Mexican, type II diabetic subjects II. Diabetes Care 1984;7: 428-33.

  5. Harris M, Eastman R, Cowie C. Symptoms of sensoryneuropathy in adults with NIDDM in the US population. DiabetesCare 1993; 16: 1446-52.

  6. Melton JL, Dyck PJ. Epidemiology. In: Diabetic Neuropathy.Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D.(Eds.) WB Saunders 1987: 27.

  7. Gómez-Pérez FJ, García Ramos G, García H, Rull JA.Neuropatía Diabética. Capítulo 52. En: Tratado deDiabetología. Gómez Pérez FJ, Rull JA (Eds.). Instituto Nacionalde la Nutrición Salvador Zubirán. 1997: 763-82.

  8. Consensus Panel: Report and recommendations of the SanAntonio Conference on Diabetic Neuropathy. Diabetes1988; 37:1000.

  9. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA etal. Acute hyperglycemia attenuates endotheliumdependentvasodilatation in humans in vivo. Circulation1998; 97: 1695-1701.

  10. Gupta S, Chough E, Daley J, Oates P, Tornheim K, RudermanN, Keaney JF. Hyperglycemia increases endothelialsuperoxide that impairs smooth muscle cell Na+ -K + -ATPaseactivity. Am J P-Cell Physiology 2002; 282: C560-C566.

  11. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, CreagerMA. Inhibition of protein Kinase Cb prevents impaired endothelium-dependent vasodilatation caused by hyperglycemiain humans. Circulation Research 2002; 90: 107-11.

  12. Way KJ, Katai N, King GL. Protein Kinase C and thedevelopment of diabetic vascular complications. DiabetMed 2001; 18: 945-59.

  13. Brownlee M. Biochemistry and molecular cell biology ofdiabetic complications. Nature 2001; 414: 813-20.

  14. King GL, Brownlee M. The cellular and molecular mechanismsof diabetic complications. Endocrinol & Metab ClinNorth Am 1996; 25: 255-70.

  15. Kamei J, Mizoguchi H, Narita M, Tseng LF. Therapeuticpotential of PKC inhibitors in painful diabetic neuropathy.Expert Opin Investig Drugs 2001;10:1653-64.

  16. Tomkin. Diabetic vascular disease and the rising star ofprotein kinase C. Diabetologia 2001; 44: 657-8-17.

  17. Hellweg R, Hartung HD. Endogenous levels of nerve growthfactor (NGF) are altered in experimental diabetes mellitus:A possible role in the pathogenesis of diabetic neuropathy.J Neurosci Res 1990; 26: 258-67.

  18. Hansson HA, Dahlin LB, Danielsen N et al. Evidenceindicating trophic importance of IGF-I in regeneratingperipheral nerves. Acta Physiol Scand 1986; 126: 609:14.

  19. Haltiwanger RS, Grove K, Philipsberg GA. Modulation ofO-linked N-acetylglucosamine levels on nuclear andcytoplasmic proteins in vivo using the peptide O-GlcNAcbeta-N-acetylglucosaminidase inhibitor O-(2acetamido-2-deoxy-D-glycopyranosylidene) amino-N-phenylcarbanate.J Biol Chem 1998; 273: 3611-17.

  20. Coppey LJ, Gellet JS, Davidson EP, Dunlap JA, Lund DD,Salvemini D, Yorek MA. Effect of M40403 treatment of diabeticrats on endoneurial blood flow, motor nerve conduction velocityand vascular function of epineural arterioles of the ciatic nerve.Br J Pharmacol 2001; 134: 21-9.

  21. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N,Greene D. A practical two sep quantitative clinical andelectrophysiological assessment for the diagnosis andstaging of diabetic neuropathy. Diabetes Care 1994; 17:1281-9 (Cuestionario de Michigan).

  22. Franse LV, Valk GD, Dekker JH , Heine RJ, Eijk JT. Numbnessof the feet is a poor indicator for polyneuropathy in type 2diabetic patients. Diabet Med 2000; 17: 105-10.

  23. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R et al. Theprevalence by staged severity of various types of diabeticneuropathy and nephropathy in a population based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993;43: 2345 (Cuestionario de Rochester).

  24. Young MJ, Boulton AJ, MacLeod AF, Williams DR, SonksenPH. A multicenter study of the prevalence of diabeticperipheral neuropathy in the United Kingdom Hospital clinicpopulation. Diabetologia 1993; 36: 150-4 (Estudio delReino Unido).

  25. Harati Y. Diabetes and the nervous system. Endocr MetabClin North Am 1996; 25: 325-59.

  26. Diabetes Control and Complications Trial. Effect of intensivetreatment of diabetes on the development and progressionof long term complications in insulin dependent diabetesmellitus. N Engl J Med 1993; 329: 977-86.

  27. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulintherapy prevents the progression of diabetic microvascularcomplications in Japanese patients with non-insulindependentdiabetes mellitus: A randomized prospective6-year study. Diab Res Clin Pract 1995; 28: 103-17.

  28. Llewelyn JG, Thomas PK, Fonseca V, King RH, Dandona P.Acute painful diabetic neuropathy precipitated by strictglycemic control. Acta Neuropathol (Berl) 1986; 72: 157.

  29. Gomez-Perez FJ, Choza R, Rios JM, Reza A, Huerta E, AguilarCA, Rull JA. Nortriptyline-fluphenazine vs carbamazepinein the symptomatic treatment of diabetic neuropathy. ArchClin Res 1996; 27: 525-29.

  30. Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinilan aldose reductase inhibitor in chronic painful diabeticneuropathy. Diabetes 1983; 32: 938-42.

  31. Boulton AJM, Levin S, Comstock. A multicenter trial of the aldosereductase inhibitor, tolrestat in patients with symptomaticdiabetic neuropathy. Diabetologia 1990; 33: 431-7.

  32. Ellenberg M. Treatment of diabetic neuropathy withdiphenylhydantoin NY State. J Med 1968; 68: 2653.

  33. Saudek CD, Werns S, Reidenberg MM. Phenytoin in thetreatment of diabetic symmetrical polyneuropathy. ClinPharmacol Ther 1977; 22: 196-9.

  34. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano-CastañedaO. Symptomatic treatment of peripheral diabeticneuropathy with carbamazepine (Tegretol): double blindcrossover trial. Diabetologia 1969; 5: 215-18.

  35. H, Carroll D, Jadad AR et al. Anticonvulsant drugs for managementof pain a systematic review. BMJ 1995; 311: 1047-

  36. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsantsfor neuropathic pain syndromes: mechanisms ofaction and place in therapy. Drugs 2000; 60: 1029-52.

  37. Eisenberg E, Luirie Y, Braker C et al. Lamotrigine reducespainful diabetic neuropathy. A randomized controlled study.Neurology 2001: 57-505.

  38. Mellegerd MA, Furlan AD, Mailis A. Gabapentin forneuropathic pain: systematic review of controlled anduncontrolled literature. Clin J Pain 2001; 17: 284-95.

  39. Backonja M, Beydoun A, Edwards KR, Schwartz SL, FonsecaV, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatictreatment of painful neuropathy in patients with diabetesmellitus: a randomized controlled trial. JAMA 1998;280: 1831-6.

  40. Backonja MM. Gabapentin monotheraphy for the symptomatictreatment of painful neuropathy: a multicenter,double blind, placebo-controlled trial in patients with diabetesmellitus. Epilepsia 1999; 40(Suppl.6): S57-9.

  41. Max MB, Culnane M, Schafer SC et al. Amitriptyline relievesdiabetic neuropathy pain with normal or depressivemood. Neurology 1987; 37: 589-96.

  42. Max MB, Lynch SA, Muir J et al. Effects of desipramine,amitriptyline and fluoxetine on pain in diabetic neuropathy.N Engl J Med 1992; 326: 1250-6.

  43. Joss JD. Tricyclic antidepressant use in diabetic neuropathy.Ann Pharmacother 1999; 33: 996-1000.

  44. Sindrup SH, Gram LF, Brosen K et al. The selective serotoninreuptake inhibitor paroxetine is effective in the treatmentof diabetic neuropathy symptoms. Pain 1990; 42: 135-44.

  45. Davis JL, Lewis SB, Gerich JE et al. Peripheral diabeticneuropathy treated with amitriptyline and fluphenazine.JAMA 1977; 238: 2291-2.

  46. Gómez-Pérez FJ, Rull JA, Dies H, Rodríguez-Rivera G,González J, Lozano-Castañeda O. Nortriptyline-fluphenazinein the symptomatic treatment of diabetic neuropathy: adouble blind crossover study. Pain 1985; 23: 395-400.

  47. Collins SL, Moore RA, MSQuery HJ, Wife P. Antidepressantsand Anticonvulsants for diabetic neuropathy and postherpeticneuralgia: a quantitative systematic review. J PainSymptom Manage 2000; 20: 449-58.

  48. Dallocchio C, Bufa C, Mazzarello P, Chiroli S. Gapapentin vsamitriptyline in painful diabetic neuropathy: an open labelpilot study. J Pain Symptom Manage 2000; 20: 280-5.

  49. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, SahagianGA. Randomized double blind study comparing the efficacyof gabapentin with amitriptyline on diabetic peripheral neuropathypain. Arch Intern Med 1999; 159: 1931-7.

  50. Baron R. Commentary. Capsaicin and nociception: from basicmechanisms to novel drugs. Lancet 2000; 356: 785. 51.

  51. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA etal. The capsaicin receptor: a heat activated ion channel inthe pain pathway. Nature 1997; 389: 816-24.

  52. The capsaicin study group. Treatment of painful diabetic neuropathywith topical capsaicine: a multicenter, double blind, vehiclecontrolled study. Arch Intern Med 1991; 151: 2225-29.

  53. Ackerman WE, Colclough GW, Juneja MM, Bellinger K. Themanagement of oral mexiletine and intravenous lidocaineto treat chronic symmetrical distal diabetic neuropathy. JKy Med Assoc 1991; 89: 500-1.

  54. Sindrup SH, Jensen TS. Efficacy and pharmacologicaltreatments of neuropathic pain: an update and effectrelated to mechanism of action. Pain 1999; 83: 389-400.

  55. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A.Anticonvulsant drugs for acute and chronic pain (CochraneReview). In: The Cochrane Library, 1, 2002, Oxford: UpdateSoftware.

  56. Davis JL. Use of sibutramine hydrochloride monohydratein the treatment of the painful peripheral neuropathy ofdiabetes. Diabetes Care 2000; 23: 1594-5.

  57. Freeman R. Human studies of recombinant nerve growthfactor and diabetic peripheral neuropathy. Eur Neurol 1999;41(Suppl. 1): 20-6.

  58. Apfel SC, Kessler JA, Adornato BT et al. Recombinant humannerve factor in the treatment of diabetic polyneuropathy.Neurology 1998; 51: 695-702.

  59. Apfel SC, Schwart S, Adornato BT. Efficacy and safety ofrecombinant human nerve growth factor in patients withdiabetic polyneuropathy: a randomized controlled trial.JAMA 2000; 284: 2215-21.




2020     |     www.medigraphic.com